IN THE SPECIFICATION:

On page 1, immediately following the title, please enter the following new paragraph:

This application is a continuation application of U.S. Patent Application Serial No. 09/633,147, filed on August 4, 2000, now abandoned, which is a divisional application of U.S. Patent Application Serial No. 08/809,105, filed on May 23, 1997, now abandoned, which is a 371 application of PCT/AU95/00606, filed on September 15, 1995, which is a continuation-in-part application of U.S. Patent Application Serial No. 08/332,562, filed on October 31, 1994 and issued as U.S. Patent No. 5,985,599. The entire disclosure of each of the foregoing prior applications is hereby incorporated by reference.

Please replace the paragraph on page 4, line 7, with the following paragraph:

Figure 5. Oligonucleotides (SEQ ID NOS 43-70) used in SOE-PCR of Example 2.

Please replace the paragraph on page 5, lines 1-2, with the following paragraph:

Figure 12. Nucleotide (SEQ ID NO: 71) and predicted amino acid (SEQ ID NO: 72) sequence of HSA: FcεRII DNA.

Please replace the paragraph on page 35, lines 12-31, with the following paragraph:

The chimeric FcγRII/FcεRI a chain receptors were generated as follows. Chimera g, e109-116: oligonucleotide pairs (NR1 + CHM10) and (CHM09 + EG5) were used to produce two fragments which were spliced together using oligonucleotides NR1 and EG5. Chimera g, e130-135: oligonucleotide pairs (NR1 + PM12) and (PM11 + EG5) followed NR1 and EG5. The sequence of the oligonucleotide used and their positions of hybridisation with the FcγRIIaNR cDNA are:

NR1, 5' - TACGAATTCCTATGGAGACCCAAATGTCTC-3' (SEQ ID NO: 1), (nucleotide position 10-30);

EG5, 5' - TTTGTCGACCACATGGCATAACG-3' (SEQ ID NO: 2), (967-981);

CHMO9, 5' - CACATCCCAGTTCCTCCAACCGTGGCACCTCAGCATG-3' (SEQ ID NO: 3), (419-437 with nucleotides 442-462 of FcεRI a chain);

CHM10, 5' - AGGAACTGGGATGTGTACAAGGTCACATTCTTCCAG-3' (SEQ ID NO: 4), (462-487 with 446-462 of FcεRI a chain),

PM11, 5' - GTGGTTCTCATACCAGAATTTCTGGGGATTTTCC-3' (SEQ ID NO: 5), (473-490 with 492-506 of FcεRI a chain);

PM12, 5' - CTGGTATGAGAACCACACCTTCTCCATCCCAC-3' (SEQ ID NO: 6), (516-531 with 491-506 of FcεRI a chain).

Please replace the paragraph on page 36, lines 3-36 thru page 37, lines 1-2, with the following paragraph:

The FcγRII Alanine point mutant cDNAs were generated using the following oligonucleotide combinations. Pro^{114}-Ala, (GBC01 + EG5) and (GBC02 + NR1); Lys^{113}-Ala: (GBC03 + EG5) and (GBC04 + NR1); Leu^{115}-Ala, (BGC05 + EG5) and (GBC06 + NR1); Val^{116}-Ala, (GBC07 + EG5) and GBC08 + NR!); Phe^{129}-Ala, (GCE01 + EG5) and (GCE02 + NR1); Ser^{130}-Ala, (GCE03 + EG5) and GCE04 + NR1); Arg/His^{131}-Ala (GCE05 +EG5) and GCE06 + NR1); Leu^{132}-Ala, (GCE07 + EG1) and GCE08 +NR1); Asp^{133}-Ala, (GCE09 + EG5) and (GCE10 + NR1); Pro^{134}-Ala; (GCE11 + EG5) and (GCE12 + NR1). Oligonucleotide NR1 and EG5 were used to splice together the two component fragments of each mutant to produce the point substituted cDNAs. The sequence of the oligonucleotides used and their positions of hybridisation with the Fcγ RIIaNR cDNA are: NR1 and EG5 as described above;

GBC01, 5' -GAAGGACAAGGCTCTGGTCAAG-3' (SEQ ID NO: 7), (nucleotide position 443-464);

GBC02, 5' -CTTGACCAGAGCCTTGTCCTTC-3' (SEQ ID NO: 8), (443-464);
GBC03, 5' -CTGGAAGGACGCTCCTCTGGTC-3' (SEQ ID NO: 9), (440-461);
GBC04, 5' -GACCAGAGGAGCGTCCTTCCAG-3' (SEQ ID NO: 10), (440-461);
GBC05, 5' -GGACAAGCCTGCTGTCAAGGTC-3' (SEQ ID NO: 11), (446-467);
GBC06, 5' -GACCTTGACAGCAGGCTTGTCC-3' (SEQ ID NO: 12), (446-467);
GBC07, 5' -GACAAGCCTCTGGCTAAGGTCAC-3' (SEQ ID NO: 13), (447-469);
GBC08, 5' -GTGACCTTAGCCAGAGGCTTGTC-3' (SEQ ID NO: 14), (447-469);
GCE01, 5' -CCCAGAAAGCTTCCCGTTTGG-3' (SEQ ID NO: 15), (490-611);
GCE02, 5' -CCAAACGGGAAGCTTTCTGGG-3' (SEQ ID NO: 16), (490-611);
GCE03, 5' -CAGAAATTCGCTCGTTTGGATC-3' (SEQ ID NO: 17), (492-614);
GCE04, 5' -GATCCAAACGAGCGAATTTCTG-3' (SEQ ID NO: 18), (492-614);
GCE05, 5' -GAAATTCTCCGCTTTGGATCCC-3' (SEQ ID NO: 19), (494-616);
GCE06, 5' -GGGATCCAAAGCGGAGAATTTC-3' (SEQ ID NO: 20), (494-616);
GCE07, 5' -ATTCTCCCGTGCTGATCCCACC-3' (SEQ ID NO: 21), (497-619);
GCE08, 5' -GGTGGGATCAGCACGGGAGAAT-3' (SEQ ID NO: 22), (497-619);

GCE09, 5' -CTCCCGTTTGGCTCCCACCTTC-3' (SEQ ID NO: 23), (500-622);

GCE10, 5' -GAAGGTGGGAGCCAAACGGGAG-3' (SEQ ID NO: 24), (500-622);

GCE11, 5' -CCGTTTGGATGCTACCTTCTCC-3' (SEQ ID NO: 25), (503-625);

GCE12, 5' -GGAGAAGGTAGCATCCAAACGG-3' (SEQ ID NO: 26), (503-625).

Please replace the paragraph on page 46, lines 5-13, with the following paragraph:

Oligonucleotide sequences and their positions of hybridization with the FcγRII a^{NR} cDNA are as follows:

CC-01, 5' -CATTCTTCCAGGCAGGAAAATCCCAG-3' (SEQ ID NO: 27), (nucleotide position 467-498);

CC-02, 5' -CTGGGATTTTCCTGCCTGGAAGAATG-3' (SEQ ID NO: 28), (467-494)

CC-03, 5' -CTTCCAGAATGCAAAATCCCAGAAATTC-3' (SEQ ID NO: 29), (473-500);

CC-04, 5' -GAATTTCTGGGATTTTGCATTCTGGAAG-3' (SEQ ID NO: 30), (473-500);

CC-05, 5' -CCAGAATGGAGCATCCCAGAAATTC-3' (SEQ ID NO: 31), (476-500);

CC-06, 5' -GAATTTCTGGGATGCTCCATTCTGG-3' (SEQ ID NO: 32), (476-500).

Please replace the paragraph on page 48, lines 16-31, with the following paragraph:

The oligonucleotides used to create the above chimeric receptors were as follows:

CC'	NR1	+	LR3
	LR4	+	EG5
EF	NR1	+	EG32
	EG33	+	EG5
G	NR1	+	LR1
	LR2	+	EG5

NR1 and EG5 are as described in Example 1.

Antisense LR1

5'-GGTTCACTGAGGCTGGTCTGGC-3' (SEQ ID NO: 33)

Sense LR2

5' -CAGCCTCAGTGAACCTGTGTACC-3' (SEQ ID NO: 34)

Antisense LR3

5'-CGTCTCTTCTGACAGGCTGCCATTGTGGAACCAC-3' (SEQ ID NO: 35)

Sense LR4

5'-GTCAGAAGAGACGAATTCACCCAGCTACAGGTCC-3' (SEQ ID NO: 36)

Antisense EG32

5'-AAATTTGGCATTCACAATATTCAAGCTGGGCTGCGTGTGG-3'
(SEQ ID NO: 37)

Sense EG33

5'-AATATTGTGAATGCCAAATTTGAAGACAGCGGGGAGTACAC-3'
(SEQ ID NO: 38)

Please replace the paragraph on page 50, line 28-35, with the following paragraph:

The HSA:FCγRII fusion protein was produced according to the following method. Oligonucleotides HT4 and HT7 were used to amplify the HSA DNA. HT4 contains the restriction site (Eco RI) for cloning and HT7 contains a sequence that overlaps with FcγRII. The sequences are as follows:

HT4 5' ATCGATGAATTCATGAAGAAGTGGTGGGTAAC 3' (SEQ ID NO: 39)

HT7 5' GGGGGAGC/GCCTAAGGCAGCTTGAC 3' (SEQ ID NO: 40)

Please replace the paragraph on page 51, lines 5-13, with the following paragraph:

Oligonucleotides HT8 and HT5 were used to amplify the required segment (extracellular domains) of FcγRII. HT8 contains a sequence that overlaps with the HSA sequence (and also oligonucleotide HT7). HT5 also contains a translation termination codon as well as a restriction site (Eco RI) for cloning purposes. The sequences of the oligonucleotides are as follows:

HT8 5'S CCTTAGGC/GCTCCCCCAAAGGCTG 3' (SEQ ID NO: 41)

HT5 5' CCCCATCATGAATTCCTATTGGACAGTGATG 3' (SEQ ID NO: 42)